A Phase I/II Study of Combination of ASTX727, Gilteritinib and Venetoclax in Patients with Relapsed/Refractory FLT3 Mutated Acute Myeloid Leukemia (AML) and Frontline FLT3 Mutated AML Patients Unfit for Chemotherapy

被引：5
|
作者：
Ong, Faustine [1 ]
Short, Nicholas [2 ]
Daver, Naval [2 ]
Kadia, Tapan M. [2 ]
DiNardo, Courtney D. [2 ]
Yilmaz, Musa [2 ]
Alvarado, Yesid [2 ]
Vaughan, Kenneth [2 ]
Pierce, Sherry A. [2 ]
Kantarjian, Hagop [3 ]
Garcia-Manero, Guillermo [2 ]
Ravandi, Farhad [4 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, CA USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Div Canc Med, Houston, TX 77030 USA
[4] Univ Texas MD Anderson Canc Ctr, Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2022年 / 140卷
关键词：
D O I：
10.1182/blood-2022-159110
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
615
引用
收藏
页码：9029 / 9031
页数：3
相关论文
共 50 条
  • [31] A Phase I/II Study of Gilteritinib and Momelotinib for Patients with Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia: A Trial in Progress
    Short, Nicholas J.
    Ravandi, Farhad
    Daver, Naval
    Dinardo, Courtney D.
    Borthakur, Gautam
    Kadia, Tapan M.
    Yilmaz, Musa
    Issa, Ghayas C.
    Abramova, Regina
    Garza, Araceli Isabella
    Kantarjian, Hagop M.
    Abbas, Hussein A.
    BLOOD, 2024, 144
  • [32] Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients
    Boluda, Blanca
    Martinez-Cuadron, David
    Algarra, Lorenzo
    Cano, Isabel
    Sayas, Maria J.
    Acuna-Cruz, Evelyn
    Blanco, Albert
    Marco-Ayala, Javier
    DeLapuerta, Rosalia
    Diaz-Gonzalez, Alvaro
    Tormo, Mar
    Rodriguez-Veiga, Rebeca
    Garcia, Raimundo
    Pinana, Jose L.
    Lopez-Pavia, Maria
    Barragan, Eva
    Amigo, Maria L.
    Sargas, Claudia
    Lopez, Aurelio
    Solana-Altabella, Antonio
    Gil, Cristina
    Eduardo Megias-Vericat, Juan
    Sanz, Miguel A.
    Montesinos, Pau
    LEUKEMIA & LYMPHOMA, 2021, 62 (11) : 2727 - 2736
  • [33] Preliminary Analysis Results of a Phase I Study of the FLT3 Inhibitor SKLB1028 in Patients with Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia
    Liu, Ting
    Zhu, Huanling
    Yao, Xuekun
    Peng, Yueying
    Wang, Yumei
    Zhan, Guoning
    Yuan, Jing
    Ni, Shaonan
    Qiao, Jie
    Hu, Zijian
    Lyu, Cheng
    BLOOD, 2019, 134
  • [34] FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
    Loschi, Michael
    Sammut, Rinzine
    Chiche, Edmond
    Cluzeau, Thomas
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (11)
  • [35] A Triplet Combination of Azacitidine, Venetoclax and Gilteritinib for Patients with FLT3-Mutated Acute Myeloid Leukemia: Results from a Phase I/II Study
    Short, Nicholas J.
    DiNardo, Courtney D.
    Daver, Naval
    Nguyen, Daniel
    Yilmaz, Musa
    Kadia, Tapan M.
    Garcia-Manero, Guillermo
    Issa, Ghayas C.
    Huang, Xuelin
    Qiao, Wei
    Sasaki, Koji
    Montalban-Bravo, Guillermo
    Chien, Kelly S.
    Borthakur, Gautam
    Delumpa, Ricardo
    Milton, Anna
    Pierce, Sherry A.
    Jabbour, Elias J.
    Konopleva, Marina
    Kantarjian, Hagop
    Ravandi, Farhad
    BLOOD, 2021, 138
  • [36] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Abhishek Maiti
    Courtney D. DiNardo
    Naval G. Daver
    Caitlin R. Rausch
    Farhad Ravandi
    Tapan M. Kadia
    Naveen Pemmaraju
    Gautam Borthakur
    Prithviraj Bose
    Ghayas C. Issa
    Nicholas J. Short
    Musa Yilmaz
    Guillermo Montalban-Bravo
    Alessandra Ferrajoli
    Elias J. Jabbour
    Nitin Jain
    Maro Ohanian
    Koichi Takahashi
    Philip A. Thompson
    Sanam Loghavi
    Kathryn S. Montalbano
    Sherry Pierce
    William G. Wierda
    Hagop M. Kantarjian
    Marina Y. Konopleva
    Blood Cancer Journal, 11
  • [37] Gilteritinib with or without venetoclax for relapsed/refractory FLT3-mutated acute myeloid leukaemia
    Kugler, Eitan
    Cohen, Inbar
    Amitai, Irina
    Ram, Ron
    Frisch, Avraham
    Nachmias, Boaz
    Canaani, Jonathan
    Moshe, Yakir
    Krayem, Baher
    Aumann, Shlomzion
    Henig, Israel
    Vainstein, Vladimir
    Shargian, Liat
    Ganzel, Chezi
    Yeshurun, Moshe
    Levi, Itay
    Raanani, Pia
    Akria, Luiza
    Ofran, Yishai
    Shimony, Shai
    Wolach, Ofir
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 205 (03) : 932 - 941
  • [38] FLT3 Inhibitors Are Promising Salvage Therapy for Relapsed or Refractory Acute Myeloid Leukemia (AML) in Patients with FLT3-ITD Mutations
    Takahashi, Koichi
    Kantarjian, Hagop M.
    Pemmaraju, Naveen
    Borthakur, Gautam
    Faderl, Stefan
    Garcia-Manero, Guillermo
    Andreeff, Michael
    Pierce, Sherry
    Ravandi, Farhad
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1547 - 1548
  • [39] Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia
    Maiti, Abhishek
    DiNardo, Courtney D.
    Daver, Naval G.
    Rausch, Caitlin R.
    Ravandi, Farhad
    Kadia, Tapan M.
    Pemmaraju, Naveen
    Borthakur, Gautam
    Bose, Prithviraj
    Issa, Ghayas C.
    Short, Nicholas J.
    Yilmaz, Musa
    Montalban-Bravo, Guillermo
    Ferrajoli, Alessandra
    Jabbour, Elias J.
    Jain, Nitin
    Ohanian, Maro
    Takahashi, Koichi
    Thompson, Philip A.
    Loghavi, Sanam
    Montalbano, Kathryn S.
    Pierce, Sherry
    Wierda, William G.
    Kantarjian, Hagop M.
    Konopleva, Marina Y.
    BLOOD CANCER JOURNAL, 2021, 11 (02)
  • [40] Gilteritinib plus azacitidine and venetoclax for FLT3-ITD mutated relapsed/refractory acute myeloid leukemia
    Chen, Nianci
    Zhou, Yile
    Tong, Hongyan
    Wei, Juying
    Lou, YinJun
    Zhou, De
    Fan, Cuihua
    Huang, Li
    Mao, Liping
    Li, Chenying
    Wang, Huafeng
    Jin, Jie
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
12345